US FDA

- Read more about U.S. FDA grant Spark Therapeutics & Pfizer Breakthrough Therapy Designation for SPK-9001
Spark Therapeutics and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to SPK-9001, the lead investigational candidate in the companies' SPK-FIX program, in development for the treatment of hemophilia B. SPK-9001, a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant, is being investigated in an ongoing Phase 1/2 trial as a potential one-time therapy.
- Read more about Relievant Medsystems, Inc. Receives FDA 510(k) Clearance for INTRACEPT
Relievant Medsystems, Inc., a privately held medical device company pioneering the therapy of nerve ablation within vertebral bodies for the treatment of chronic low back pain, announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the INTRACEPT® Intraosseous Nerve Ablation System.
- Read more about CytoDyn Submits Orphan Drug Application to FDA for Pretreatment With PRO 140
CytoDyn Inc. announces that it has submitted to the U.S. Food And Drug Administration (FDA) an application for orphan drug designation for the use of PRO 140 (humanized monoclonal antibody to CCR5) in the pretreatment of HIV Type-1 (HIV-1) infection in treatment-naïve adults while they are waiting for drug resistance assay results to construct a subsequent Highly Active Antiretroviral Therapy (HAART) regimen. The generation of these assay results typically takes approximately two weeks.
- Read more about Advaxis’ AXAL Receives Fast Track Designation by the FDA
Advaxis, Inc. announced that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead immunotherapy candidate, axalimogene filolisbac (AXAL), as a Fast Track product for adjuvant therapy for high-risk locally advanced cervical cancer patients. The investigation of AXAL in this under-served population will be conducted in accordance with the Special Protocol Assessment (SPA) recently granted by the FDA.
- Read more about FDA Authorize Viracor-IBT Laboratories, Inc.’s Zika Virus RT-PCR Test for Emergency Use
Viracor-IBT Laboratories, Inc., a wholly-owned subsidiary of Eurofins Scientific (EUFI.PA), announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Zika Virus Real-time RT-PCR assay.
24 October 2012

News

Daily Updated Pharma-News regarding R&D, FDA, F&D, Pharmaceuticals industries, Hospital Pharmacy and Pharmaceutical Development ...

[adsense:336x280:8701650588]
13 July 2010

More Damning Evidence Against GSK and FDA on Rosiglitazone

Further evidence has come to light suggesting that GlaxoSmithKline knew about an increased cardiac risk with the diabetes drug rosiglitazone (Avandia) as early as 2001 but withheld the data and that certain officials at the FDA conspired with the company to minimize the impact of later safety results. The news comes on the same day that the FDA advisory panel starts its two-day hearing on the cardiovascular safety of the drug.
26 April 2010

FDA Launches Campaign to Improve Infusion-Pump Safety

The US Food and Drug Administration (FDA) today unveiled an ambitious campaign to improve the safety of external infusion pumps, which have triggered 56,000 FDA adverse event reports linked to more than 500 deaths and 87 product recalls from 2005 through 2009, according to the agency.

The campaign mostly affects the makers of external infusion pumps, which may find FDA inspectors visiting their plants to ensure that safe manufacturing and testing processes are in place.
22 April 2010

FDA warning to Propylthiouracil

April 21, 2010 — The US Food and Drug Administration (FDA) has added a boxed warning to the drug label for propylthiouracil about reports of severe liver injury and acute liver failure, in some cases fatal, that have been reported in both adult and pediatric patients who used this drug.

Notice of the warning was sent today in an alert from MedWatch, the FDA's safety information and adverse event reporting program.

[adsense:336x280:8701650588]
17 April 2010

FDA Announces Phase Out of CFC-Based Asthma and COPD Inhalers

April 16, 2010 — In compliance with a rule about ozone-depleting substances, the US Food and Drug Administration (FDA) has announced that 7 available asthma and chronic obstructive pulmonary disease (COPD) metered-dose inhalers that use chlorofluorocarbons (CFCs) as propellants are being removed from the marketplace.